Saturday, June 9, 2012

Astellas and Ambit Initiate Phase 2b Dose Finding Study of Quizartinib as ... - MarketWatch (press release)

acklinegymejac1362.blogspot.com


Astellas and Ambit Initiate Phase 2b Dose Finding Study of Quizartinib as ...

MarketWatch (press release)


TOKYO and SAN DIEGO, June 4, 2012 /PRNewswire via COMTEX/ -- Astellas Pharma Inc. (tokyo:4503)(tokyo:Astellas) and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in ...


Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

News-Medical.net



 »

No comments:

Post a Comment